NCT04083976 2026-03-19RAGNARJanssen Research & Development, LLCPhase 2 Active not recruiting316 enrolled 15 charts
NCT05014828 2025-08-24To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid TumorsBeiGenePhase 2 Completed58 enrolled 16 charts
NCT04488003 2024-06-04Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF AlterationsBioMed Valley Discoveries, IncPhase 2 Terminated104 enrolled 13 charts